Anyi Beauty Acne Patch

Description

The product is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. Each tablet is debossed with "XYZ" on one side and "123" on the opposite side. It contains 500 mg of the active ingredient. The formulation includes the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, talc, hypromellose, titanium dioxide, polyethylene glycol, and iron oxides (red and yellow).

Uses and Indications

This drug is indicated for the treatment and prevention of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to ensure that the skin is thoroughly cleansed prior to the application of the patch. The patch should be applied directly to the affected area.

Initial treatment should begin with one application daily. Based on the patient's response and as directed by a physician, the frequency of application may be gradually increased to two or three times daily.

In cases where bothersome dryness or peeling occurs, it is recommended to reduce the frequency of application to once daily or every other day. To remove the patch, gently peel it back and discard it appropriately.

Contraindications

Use is contraindicated in individuals who are pregnant or breastfeeding unless directed by a healthcare professional. In the event of accidental ingestion resulting in an adverse reaction, immediate medical assistance should be sought or contact with a Poison Control Center is advised.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes, lips, and mouth during application. In the event of contact, the affected area should be flushed thoroughly with water to mitigate any potential irritation.

The concurrent use of this product with other topical acne medications may increase the likelihood of skin irritation and dryness. To minimize the risk of adverse effects, it is recommended that only one topical acne medication be used at a time.

Healthcare professionals should advise patients who are pregnant or breastfeeding to consult with a healthcare provider prior to use. In cases of accidental ingestion leading to an adverse reaction, immediate medical assistance should be sought, or the Poison Control Center should be contacted.

In summary, careful adherence to these warnings and precautions is essential for the safe use of this product.

Side Effects

Patients should be aware that this product is for external use only. It is important to avoid contact with the eyes, lips, and mouth; in the event of contact, the affected area should be flushed thoroughly with water.

Skin irritation and dryness are common adverse reactions associated with the use of this product. The likelihood of experiencing these reactions may increase if patients concurrently use another topical acne medication. Therefore, it is recommended that only one topical acne medication be used at a time to minimize the risk of irritation.

Drug Interactions

Skin irritation and dryness may be exacerbated when using multiple topical acne medications concurrently. It is advised that only one topical acne medication be utilized at a time to minimize the risk of irritation.

No specific drug or laboratory test interactions have been identified in the available data.

Packaging & NDC

Below are the non-prescription pack sizes of Anyi Beauty Acne Patch (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. Additionally, it is important for caregivers to consult a healthcare professional if the patient is pregnant or breastfeeding before administering this medication.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to discuss their individual circumstances with their healthcare provider to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Furthermore, specific antidotes or treatments may be indicated depending on the substance involved in the overdose. It is crucial for healthcare professionals to consult relevant clinical guidelines and toxicology resources to determine the most effective management strategies tailored to the individual case.

In summary, while no specific overdosage information is available, vigilance and prompt intervention are paramount in managing potential overdose situations.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to consult with a healthcare professional if they are pregnant or breastfeeding before using this medication. It is important for patients to understand the potential risks and benefits associated with the use of the medication during these periods.

Additionally, healthcare providers should inform patients about the importance of seeking immediate medical assistance or contacting a Poison Control Center in the event of accidental ingestion and subsequent adverse reactions. This guidance is crucial for ensuring patient safety and appropriate management of any potential emergencies.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool, dry place, ensuring it is kept away from direct sunlight to maintain its integrity and efficacy. Proper storage conditions are crucial for preserving the quality of the product throughout its shelf life.

Additional Clinical Information

The route of administration for the medication is topical. Patients are advised to start with one application daily, with the option to gradually increase to two or three times daily as needed or directed by a healthcare professional. Should bothersome dryness or peeling occur, the application frequency should be reduced to once a day or every other day.

Clinicians should counsel patients to avoid contact with the eyes, lips, and mouth, and to flush thoroughly with water if contact occurs. The likelihood of skin irritation and dryness increases if another topical acne medication is used concurrently; therefore, it is recommended to use only one topical acne medication at a time if irritation arises. Pregnant or breastfeeding patients should consult a healthcare professional before use. In the event of accidental ingestion leading to an adverse reaction, patients should seek medical assistance or contact a Poison Control Center.

Drug Information (PDF)

This file contains official product information for Anyi Beauty Acne Patch, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)